A Double-blind Desipramine Substitution During Long-term Clomipramine Treatment in Children and Adolescents With Obsessive-Compulsive Disorder

Archives of General Psychiatry

Volumn 48, Issue 10, 1991, Pages 922-927

  Leonard, Henrietta L ^a   Swedo, Susan E ^a   Lenane, Marge C ^a   Rettew, David C ^a   Cheslow, Deborah L ^a   Hamburger, Susan D ^a   Rapoport, Judith L ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIPRAMINE; DESIPRAMINE;

ADOLESCENT; ARTICLE; CHILD; CLINICAL TRIAL; COMPULSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; NIGHTMARE; OBSESSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREMOR; XEROSTOMIA;

ADOLESCENT; AGE FACTORS; CHILD; CLOMIPRAMINE; DESIPRAMINE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; OBSESSIVE-COMPULSIVE DISORDER; PSYCHIATRIC STATUS RATING SCALES; RECURRENCE;

EID: 0026072115     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.1991.01810340054007     Document Type: Article

References (39)

1. Zohar J, Insel TR. Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment and pathophysiology. Biol Psychiatry. 1987;22:667-687.
2. Goodman WK, Price LH, Delgado PL, Palumbo J, Krystal JH, Nagy LM, Rasmussen SA, Heninger GR, Charney DS. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry. 1990; 47:577-585.
3. Jenike MA, Buttolph L, Baer L, Ricciardi J, Holland A. Open trial of fluoxetine in obsessive-compulsive disorder. Am J Psychiatry. 1989;146:909-911.
4. Prien RF, Kupfer DJ. Continuation drug therapy for major depressive episodes: how long should it be maintained? Am J Psychiatry. 1986;143:18-23.
5. Seager CP, Bird RL. Imipramine with electrical treatment in depression: a controlled trial. J Ment Sci. 1962;108:704-707.
6. Mindham RH, Howland C, Sheperd M. An evaluation of continuation therapy with tricyclic antidepressants in depressive illness. Psychol Med. 1973;3:5-17.
7. Prien RF, Klett CH, Caffey EM. Lithium carbonate and imipramine in prevention of affective episodes. Arch Gen Psychiatry. 1973;29:420-425.
8. Klerman GL, DiMascio A, Weissman M, Prusoff B, Paykel ES. Treatment of depression by drugs and psychotherapy. Am J Psychiatry. 1974;131:186-191.
9. Coppen A, Montgomery S, Rao V, Bailey J, Jorgensen A. Continuation therapy with amitriptyline in depression. Br J Psychiatry. 1978;133:28-33.
10. Stein MK, Rickels K, Weise CC. Maintenance therapy with amitriptyline: a controlled trial. Am J Psychiatry. 1980; 137:370-371.
11. Weiner A, Reich T, Robins E, Fishman R, Van Doren T. Obsessive compulsive neurosis: record, follow-up and family studies, I: inpatient record study. Compr Psychiatry. 1976; 17:527-539.
12. Zeitlin H. The Natural History of Psychiatric Disorder in Children. New York, NY: Oxford University Press Inc; 1986.
13. Thoren P, Asberg M, Cronholm B, Jornestedt L, Traskman L. Clomipramine treatment of obsessive-compulsive disorder, I: a controlled clinical trial. Arch Gen Psychiatry. 1980;37:1281-1285.
14. Asberg M, Thoren P, Bertilsson L. Psychopharmacologic treatment of obsessive-compulsive disorder. Psychopharmacol Bull. 1982;18:13-21.
15. Fontaine R, Chouinard G. Fluoxetine in the long-term maintenance treatment of obsessive-compulsive disorder. Psychiatr Ann. 1989;19:88-91.
16. Flament M, Rapoport J, Berg C, Sceery W, Kilts C, Mellstrom B, Linnoila M. Clomipramine treatment of childhood obsessive-compulsive disorder. Arch Gen Psychiatry. 1987; 42:977-983.
17. Leonard HL, Swedo SE, Rapoport JL, Koby EV, Lenane MC, Cheslow DL, Hamburger SD. Treatment of obsessivecompulsive disorder with clomipramine and desipramine in children and adolescents. Arch Gen Psychiatry. 1989;46:1088-1092.
18. Pato MT, Zohar-Kadouch R, Zohar J, Murphy DL. Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder. Am J Psychiatry. 1988; 145:1521-1525.
19. Zohar J, Fux M, Taub M, Insel TR. Specificity of clomipramine response in obsessive-compulsive disorder. Presented at the 28th annual meeting of the American College of Neuropsychopharmacology; December 15, 1989; Maui, Hawaii.
20. Cassano GB, Petracca A, Perugi G, Nisita C, Musetti L, Mengali F, McNair DM. Clomipramine for panic disorder, I: the first 10 weeks of a long-term comparison with imipramine. J Affective Disord. 1988;14:123-127.
21. Insel TR, Mueller EA, Alterman I, Linnoila M, Murphy DL. Obsessive compulsive disorder and serotonin: is there a connection? Biol Psychiatry. 1985;20:1174-1188.
22. Herjanic B, Campbell JW. Differentiating psychiatrically disturbed children on the basis of a structured interview. J Abnorm Child Psychol. 1977;5:127-135.
23. Welner Z, Reich W, Herjanic B, Jung KG, Amado H. Reliability, validity, and parent-child agreement studies of the Diagnostic Interview for Children and Adolescents (DICA). J Am Acad Child Adolesc Psychiatry. 1987;26:649-653.
24. Berg CJ, Rapoport JL, Flament MF. The Leyton Obsessional Inventory-Child Version. J Am Acad Child Adolesc Psychiatry. 1986;25:84-91.
25. Baxter LR, Schwartz JM, Mazziotta JC, Phelps ME, Mazziotta JD, Guze BH, Schwartz JM, Selin CE. Local cerebral glucose metabolic rates in obsessive-compulsive disorder. Arch Gen Psychiatry. 1987;44:211-218.
26. Rapoport J, Elkins R, Mikkelsen E. Clinical controlled trial of clomipramine in adolescents with obsessive-compulsive disorder. Psychopharmacol Bull. 1980;16:61-63.
27. Asberg M, Montgomery SA, Perris C, Schalling D, Sedvall G. A comprehensive psychopathological rating scale. Acta Psychiatr Scand. 1978;271:5-27.
28. Murphy DL, Pickar D, Alterman IS. Methods for the quantitative assessment of depressive and manic behavior. In: Burdock EL, Sudilovsky A, Gershon S, eds. The Behavior of Psychiatric Patients. New York, NY: Marcel Dekker Inc; 1982:355-392.
29. Insel TR, Murphy DL, Cohen RM, Alterman I, Kilts C, Linnoila M. Obsessive-compulsive disorder: a double-blind trial of clomipramine and clorgyline. Arch Gen Psychiatry. 1983;40:605-612.
30. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Psychol. 1967;6:278-296.
31. Campbell M, Palij M. Measurement of side effects including tardive dyskinesia. Psychopharmacol Bull. 1985; 21:1063-1082.
32. Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, Charney DS. The Yale-Brown Obsessive Compulsive Scale (Y-BOCS), II: validity. Arch Gen Psychiatry. 1989;46:1012-1016.
33. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleishman RL, Hill CL, Heninger GR, Charney DS. The Yale Brown Obsessive Compulsive Scale (Y-BOCS), I: development, use and reliability. Arch Gen Psychiatry. 1989;46:1006-1011.
34. SAS User's Guide: Statistics. 5th ed. Cary, NC: SAS Inc; 1985.
35. Kirk RE. Experimental Design: Procedures for the Behavioral Science. Pacific Grove, Calif: Brooks/Cole Publishing Co; 1982.
36. Swedo SE, Rapoport JL, Leonard HL, Lenane M, Cheslow D. Obsessive compulsive disorder in children and adolescents: clinical phenomenology of 70 consecutive adults. Arch Gen Psychiatry. 1989;46:335-341.
37. Rachman S, Cobb J, Grey S, McDonald B, Mawson D, Sartory G, Stern R. The behavioral treatment of obsessionalcompulsive disorders, with and without clomipramine. Behav Res Ther. 1979;17:467-478.
38. Marks, IM, Stern RS, Mawson D, Cobb J, McDonald R. Clomipramine and exposure for obsessive compulsive rituals. Br J Psychiatry. 1980;136:1-25.
39. Baer L, Minichiello WE. Behavior therapy for obsessivecompulsive disorder. In: Jenike MA, Baer L, Minichiello WE, eds. Obsessive-Compulsive Disorders: Theory and Management. 2nd ed. St Louis, Mo: Mosby—Year Book; 1990.